Ionis has faced a declining revenue trajectory over the medium term, with a 1.4% average annual drop over three years versus 5.3% growth for the S&P 500. The last twelve months reflect a steeper 7.6% ...

Researchers at the National Graphene Institute have developed a new type of antimicrobial coating that could improve hygiene across health care, consumer, and industrial products. Working in ...

Ionis Pharmaceuticals IONS announced that the FDA has granted the Breakthrough Therapy designation to its pipeline candidate, ION582, for the treatment of Angelman syndrome (AS), a rare neurological ...

Chief Scientific Officer Frank Bennett executed a pre-planned stock sale on Monday, selling 10,000 shares at a weighted average price of $43.98 per share, generating approximately $439,776 in proceeds ...

Ionis Pharmaceuticals IONS announced positive topline results from a pivotal phase III study evaluating its investigational RNA-targeted therapy zilganersen for treating a rare neurological condition ...